Literature DB >> 17576842

Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

Lisa A Kroeger1, Laurie B Hovde, Isaac F Mitropoulos, Jeremy Schafer, John C Rotschafer.   

Abstract

Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime. Pre- and postexposure colistin sulfate MICs were determined. A single daily dose of colistin methanesulfonate combined with continuous-infusion ceftazidime prevented regrowth and postexposure MIC increases.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576842      PMCID： PMC2043208          DOI： 10.1128/AAC.01433-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

Authors:  A C Gales; R N Jones; K R Forward; J Liñares; H S Sader; J Verhoef
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  The pharmacokinetics of colistin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; M A O'Riordan; J L Blumer
Journal:  J Clin Pharmacol       Date:  2001-06       Impact factor: 3.126

3.  Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.

Authors:  James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Ian R Friedland; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings.

Authors:  José Garnacho-Montero; C Ortiz-Leyba; Esteban Fernández-Hinojosa; Teresa Aldabó-Pallás; Aurelio Cayuela; Juan A Marquez-Vácaro; Andrés Garcia-Curiel; F J Jiménez-Jiménez
Journal:  Intensive Care Med       Date:  2005-03-23       Impact factor: 17.440

5.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

6.  Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.

Authors:  R A Zabinski; K Vance-Bryan; A J Krinke; K J Walker; J A Moody; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

7.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

8.  Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
  8 in total
  8 in total

1.  Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.

Authors:  N C Gordon; K Png; D W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

Review 2.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  An ompR-envZ Two-Component System Ortholog Regulates Phase Variation, Osmotic Tolerance, Motility, and Virulence in Acinetobacter baumannii Strain AB5075.

Authors:  Kyle A Tipton; Philip N Rather
Journal:  J Bacteriol       Date:  2017-01-12       Impact factor: 3.490

Review 4.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.

Authors:  Ronen Ben-Ami; Russell E Lewis; Jeffrey Tarrand; Konstantinos Leventakos; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

7.  In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam.

Authors:  Vien Le Minh; Nguyen Thi Khanh Nhu; Voong Vinh Phat; Corinne Thompson; Nguyen Phu Huong Lan; Tran Vu Thieu Nga; Pham Thi Thanh Tam; Ha Thanh Tuyen; Tran Do Hoang Nhu; Nguyen Van Hao; Huynh Thi Loan; Lam Minh Yen; Christopher M Parry; Ho Dang Trung Nghia; James I Campbell; Tran Tinh Hien; Louise Thwaites; Guy Thwaites; Nguyen Van Vinh Chau; Stephen Baker
Journal:  J Med Microbiol       Date:  2015-07-17       Impact factor: 2.472

8.  Anti-Acinetobacter baumannii single-chain variable fragments show direct bactericidal activity.

Authors:  Eilnaz Basardeh; Somayeh Piri-Gavgani; Behnoush Soltanmohammadi; Mostafa Ghanei; Mir Davood Omrani; Mahdieh Soezi; Mohammad Ali Shokrgozar; Masoumeh Azizi; Abolfazl Fateh; Farzam Vaziri; Seyed Davar Siadat; Zahra Sharifzadeh; Fatemeh Rahimi-Jamnani
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.